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Only recently has the nephrology community moved beyond
a fairly singular focus on terminal kidney failure to embrace
population-based studies of earlier stages of disease, its
markers and risk factors, and of interventions. Observations
in developing countries, and in minority, migrant, and
disadvantaged groups in westernized countries, have
promoted these developments. We are only beginning to
interpret renal disease in the context of public health history,
social and health transitions, changing population
demography, and competing mortality. Its intimate
relationships to other health issues are being progressively
exposed. Perspectives on the multideterminant etiology of
most disease and the pedestrian nature of most risk factors
are maturing. We are challenged to reconcile epidemiologic
patterns with morphology in diseased renal tissue, and to
consider structural markers, such as nephron number and
glomerular size, as determinants of disease susceptibility.
New work force models are mandated for population-based
studies and intervention programs. Intervention programs
need to be integrated with other chronic disease initiatives
and nested in a matrix of systematic primary care, and
although flexible to changing needs, must be sustained over
the long term. Cross-disciplinary collaboration is essential in
designing those programs, and in promoting them to
health-care funders. Substantial expansion and restructuring
of the discipline is needed for the nephrology community to
participate effectively in those processes.
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Perspectives in nephrology have only recently expanded to
include population-based patterns of renal disease.1 Ob-
servations in developing countries, and in minority, migrant
and disadvantaged groups in Westernized countries, have
helped stimulate these developments. The rapidly changing
health status of these populations2,3 and their high rates of
risk factors are exposing phenomena that are more obscured
in the broader population, and they face special challenges in
terms of competing health issues, health-care delivery,
program development and resource allocation. The potential
relevance of the themes exposed in those populations to
health and health systems in the broader environment needs
to be constantly evaluated.
Initiatives of the Commission for the Global Advancement
of Nephrology (COMGAN) within the International Society
of Nephrology, and, more recently, of the International
Federation of Kidney Foundations have promoted this area of
enquiry, and the literature is proliferating.4–11
New ideas are developing about renal disease itself, and
about research, practice and policy. Renal health is being
positioned more centrally in the context of overall health and
wellbeing. Changes embrace definitions, concepts of causa-
tion, considerations of transition and social change, a new
focus on prevention, attention to previously undervalued
therapies, and challenges to current workforce models. We
are propelled into wider considerations of epidemiology,
statistics, public health, health services, health economics,
health policy and advocacy, and into expanded collabora-
tions. These developments invite redefinition of the discipline
itself and of its boundaries.
CHANGING PATTERNS AND CONCEPTS OF RENAL DISEASE
In renal disease, as in health generally, change is constant. In
its short history, nephrology in Western countries has seen
the rise and fall of analgesic nephropathy, striking reductions
in post-streptococcal glomerulonephritis, and in malignant
and accelerated hypertension, the dramatic emergence of
renal disease in type II diabetics, an increase in focal
segmental glomerulosclerosis and the appearance of nephro-
pathies associated with HIV/AIDS, and with its treat-
ment.12–16 In several continents, renal disease risk has been
delineated along ethnic and geographic lines and socio-
economic gradients.12–22 In developing countries a multitude
of problems are being exposed.23–28 The increasing impact of
non-communicable chronic disease and the pandemic of
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HIV/AIDS are superimposed on backgrounds of various
glomerulonephritides, infections and post-infectious condi-
tions, hepatitis B and other viral infections, malignant
hypertension, stones, obstruction, tuberculosis, toxicities
and poisonings, obstetric and traumatic causes, and special
family clusterings.
Studies of patterns and trends require definition of
markers. Comparison of inventories of terminal disease has
considerable limitations. Terminal disease is poorly captured
by death registries and by hospital admission data, even in
Western settings,29–32 while enumeration of people on renal
replacement therapy (RRT) misses the X50% of people with
end-stage renal disease to whom RRT is not applied even in
countries with open access to treatment,33 and is irrelevant in
regions where RRT is not widely available. Earlier stages of
disease can be assessed through proteinuria, albuminuria or
glomerular filtration rate estimates, which can be modeled
at various arbitrary cutoffs, as well as continuous variables,
which better reflects evolution of disease. However, thus far,
most systematic population-based surveys have been in
affluent countries where RRT rates are already best docu-
mented.33–36 Furthermore, the predictive values of various
markers for adverse outcomes have been defined in only a
few of those studies, and their applicability in other situations
is uncertain.
Multi-determinant models are critical to understanding
community-based burdens of renal disease.37–39 These
models are underpinned by the independent and significant
associations of several factors with renal disease in multi-
variate analyses, and they imply that different risk factors can
act simultaneously or sequentially to amplify the expression
and progression of disease. They predict high rates of disease
in environments with high densities of strong risk factors and
they allow estimates of the proportion of the disease burden
associated with individual risk factors. Significant associa-
tions do not prove cause and effect, however, and models
cannot assess contributions of factors not included in them.
Multi-determinant modelling shows that most of the
population-based burden of chronic kidney disease is not of
obscure or exotic causes, but is associated with garden-variety
factors that determine health profiles more generally.37,39–52
Among Australian Aborigines for example, albuminuria is
independently predicted by current body size, features of the
metabolic syndrome, blood pressure, birth weight (inversely),
infections, remote post-streptococcal glomerulonephritis,
heavy drinking, and grand multiparity. Different populations
can have different weightings of common risk factors, as well
as risk factors specific to their own circumstances.
In all populations studied so far, body weight or central fat
is a powerful risk determinant. Modest increases in body fat
might have a trivial impact on renal disease burden when
acting in isolation, but a substantial impact when other risk
factors are also operating, whereas marked overweight should
be important in all circumstances. Complicating dysglycemia,
overt diabetes, and higher blood pressures further compound
risk. The secular increase in body mass index in most
countries is undoubtedly contributing to the rising global
burden of kidney disease. Birth weight is also an important
determinant of renal disease risk. In many developing
countries, compatible with smaller stature of their adult
populations, birth weights are lower than those in Westernized
countries, and most disadvantaged populations have, in
addition, high rates of superimposed intrauterine growth
retardation. Improved survivals of high-risk infants and
progressive population-based increases in body fat collude to
educe and exacerbate expression of chronic disease in
adolescence and adult life. In affluent societies, the increasing
retrieval of babies of very low birth weight associated with
prematurity will likely produce a group with accentuated
susceptibility to renal and related conditions in later life.
Cigarette smoking, which is actively promoted in developing
countries, compromises fetal growth and nephron endowment
and exacerbates renal disease throughout life, and is profoundly
underrated as a risk factor. Alcohol use acts similarly at both
the fetal and postnatal levels. Poor nutrition, and specifically
lack of fresh fruit and vegetables, increases renal risk, as do
inactivity, use of recreational drugs, and some analgesics.
With this broad slew of associations, small wonder then,
that renal disease connotes generally poor health and marks
all-cause mortality so strongly.33,53,54
On first inspection, the concept of disease promoters is
aligned with this multi-determinant view. This was originally
defined through the greatly exacerbated risk that type II
diabetes and higher blood pressures seem to confer for renal
disease of all common types.45–47 However, a cause-and-effect
notion is being supplanted by the view that albuminuria,
rising blood pressures, insulin resistance, and cardiovascular
risk are all elements of a renal/metabolic/vascular syndrome.
Indeed, albuminuria, which probably reflects microvascular
injury, often precedes the development of diabetes and
cardiovascular disease, and predicts most of the morbid and
fatal outcomes associated with them.54–63
Life course theory of disease causation can be evaluated
through multi-determinant models.64 Any number of
candidate modulators, such as racial, ethnic, demographic,
social and economic groupings, genotypes, parental char-
acteristics, prenatal exposures, birth characteristics, and
infant and childhood experiences, can all be evaluated in
the context of the current features of individuals under study.
Potential downstream mediators of determinants can also be
evaluated. For example, how do nutrition, stress, health
behaviors and health services utilization contribute to
socioeconomic or ethnic risk stratifications, and, by what
mechanisms do they facilitate disease expression?15,17–20,65–68
Cardiovascular epidemiologists are well ahead in the
development of such a multi-determinant concept. They
have defined a ‘polyfactorial’ background for ischemic heart
disease, and applied predictive formulae to individuals and to
populations. In their models, too, garden-variety risk factors
dominate, but they have also defined important contri-
butions from psychosocial factors, which have been scantily
studied in the context of renal disease. Moreover, their
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models show that 95% of ischemic heart disease events are
associated with risk factors that can potentially be modified,
which probably applies, but must be more rigorously
evaluated, for renal disease.69–71
Renal structural findings need to be reconciled with
epidemiologic profiles and a multideterminant view. Autopsy
studies72–80 have recently defined a 410-fold range in
nephron number among ‘normal’ people, and birthweight.
directly, is a powerful determinant. It seems likely that low
nephron endowment predisposes to renal disease and
possibly to essential hypertension as well. Evidence is also
accruing that glomerulomegaly marks susceptibility to renal
disease, and potentially accelerates loss of renal function
through hyperperfusion and progressive glomerulosclerosis.
Glomerular enlargement, in turn, is significantly correlated
with nephron number, inversely, and with adult body
size, directly. The compounding effects of lower birth
weights and higher adult weight on glomerular volume
might mediate their mutual amplifying effect on renal risk.
Findings in diseased renal biopsies in some high-risk
populations also weigh against a single cause hypothesis;
they show the usual spectrum of morphologic ‘entities’ and
often mixed lesions in individuals (diabetic change, post-
infectious change, mesangial immune complex deposition,
interstitial nephritis, etc.), against a background of glomer-
ulomegaly, mesangial expansion and proliferation, and
glomerulosclerosis.81–89
Disease trends should be interpreted in light of public
health history generally, the experience of other popula-
tions90,91 and the social and health experiences of the group
under study. Increases in disease burden do not all flow from
failures in public health or health services; instead, they often
mark past triumphs, which are reflected in population
growth, increasing longevity and reduced competing mor-
tality. Life expectancy doubled in Western countries in the
20th century, permitting the more fullsome expression of
chronic diseases and their complications, better management
of people with diabetes and cardiovascular disease permits
more to survive to progress to renal failure, and the striking
reductions in infant mortality observed in most countries
have allowed more low birth weight infants to survive to
adult life, at accentuated risk for chronic disease. In addition,
secular trends of higher BMIs derive, in part, from improved
birthweights and better postnatal nutrition, with moderate
degrees of overweight marking a survival advantage in some
populations.92 Finally, we need to be realistic in aspirations
for prevention and treatment, and accept the ultimate
inevitability of organ system failure and death, whether the
focus is prolonging life in an individual in a well-resourced
system or in assessing ‘best-buys’ in health services for whole
populations.
IMPLICATIONS FOR TRAINING AND PRACTICE
To drive effective change, we need to broaden our knowledge
base, adapt our professional identities, refashion curricula,
training streams, granting priorities and methods of sharing
information, collaborate with disciplines with shared inter-
ests, and restructure workforce models.
There is a growing initiative of assistance to developing
countries. Most of the early focus was on technologic training
and on dialysis and transplantation, but there is now
increasing demand for help with programs for primary and
secondary prevention.
Intervention programs are needed in all populations with
significant burdens of renal and related chronic disease. The
argument that they are most especially applicable to
developing countries, where, and because, RRT is not widely
available, is flawed.93 It ignores the X10-fold toll from non-
renal causes that albuminuria or reduced glomerular
filtration rate predict, and which can be modified by
intervention. It propagates a focus on RRT in assistance
programs, which consumes limited resources, and provides
role models, aspirations, and training streams discordant
with the dominant needs of the country. Finally, it implies
that, if RRT is available, end-stage renal disease is an
acceptable outcome, whereas life, especially on dialysis, is
miserable and short, and the treatments are very costly.
Western countries, which are still sorting out their own
approaches to prevention, should be wary of categorical
recommendations for developing countries, but should help
them to define their own needs. All countries and regions
have different competing social and health priorities,
different burdens of renal and cardiovascular disease,
different workforce issues, and variable access to reagents,
therapies and monitoring capabilities. It is important to
articulate, in advance, whether individual projects constitute
research or case-finding for treatment, for they differ in
intensity, scope, and expectations for sustainability.
Pilot studies are important, and iterative cycles of imple-
mentation, evaluation, and modification should be in-
cluded in all definitive projects, so that they remain on
target.63,94 In many settings, reagents and equipment are
more prohibitive cost items than labor, and relatively modest
contributions by Western standards can be critical. Targeted
redirection of some of the extravagant spending on our own
international meetings could help many programs get
underway.
Ideas about diagnosis are changing. For case-finding, the
definition of target groups is important. If renal disease in a
given population is largely segregated among people who are
obese, diabetic, or hypertensive, more widespread screening
is wasteful. The routine inclusion of serum creatinine in the
screening of people without proteinuria or hypertension can
scarcely be mandated if there is little significant renal
insufficiency in such people. In evaluating people with
clinical renal disease, the specific rather than general
application of immune serologic tests, imaging, and biopsy
should be considered, by assessing likelihood of abnormal-
ities, and whether findings will change management.95 These
approaches might be more rigorously applied where
resources are restricted, but they are also relevant in the
broader practice environment. All, however, require some
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knowledge of the local epidemiology of renal disease, and
therefore, an attempt to define it.
Treatment approaches, too, should be broadening. We
need to evaluate remedies to supplement or substitute for
RRT, including gut-based therapies with osmotic agents,
sorbents, bacteria, enzymes, and low protein diets, etc.96–98 At
earlier stages of disease, blood pressure should be targeted by
whatever drugs are available and tolerated, but access to
angiotensin-converting enzyme inhibitor and angiotensin
receptor blocker in all regions must be promoted. In view of
the usual need for multiple drugs, we should urge
pharmaceutical companies to develop a range of therapeutic
dose polypills.63,99 Innovative methods of slow-release drug
delivery should also be explored, including creams, patches,
implants, and perhaps inhalation. Finally, in the Western
world, pharmacologic primary prevention in high-risk
subjects is being discussed, originally in the context of
controlling body weight and preventing diabetes, and now in
preventing renal disease itself.100,101
The renal-care workforce model operating in Western
counties is ill-suited to population studies and to prevention
and treatment programs and is incompatible with the needs
of the developing world. Primary prevention, case-finding,
and modification of existing disease should be conducted in
the primary care setting, and integrated with approaches to
all regionally important health issues. A ‘body parts’
approach, a disdainful term coined by Aboriginal Australians,
who have been victims of many poorly resourced, unsus-
tained, vertical programs, is inefficient and conflicts with
holistic primary health care. With good training, protocols,
backup, and adequate resources, health workers and com-
munity liaison people can run testing and treatment
programs.63 Nurses and generalist doctors can handle
complex cases, design program audits, and modify inter-
ventions, whereas specialists should be redefining existing
concepts, analyzing emerging problems, and updating
approaches.63,102 All can participate in policy development
and advocacy.
INFLUENCING HEALTH-CARE POLICY
Little will be achieved without effective input into policy.
Several ingredients are needed: analysis of needs, articulation
of the issues, outlines of potential solutions and feasible
programmatic structures, and strong and enduring links with
decision makers. At the minimum, health-care funders must
be persuaded to support prevention programs and strategic
research to stay abreast of changing disease patterns.
Potential incentives include reductions in premature death
and disability from chronic diseases, including diabetes and
cardiovascular disease, and for Westernized countries, cost-
savings through dialysis avoided or delayed.103,104 In most
instances, responsibility for those programs will be with
government,105 and therein, with stable government struc-
tures, lies their best hope for sustainability.
Programs should represent integrated, rather than speci-
alty-specific approaches and be nested within primary care
structures. This means adapting existing structures and
building primary care systems when none currently exist.
Practical advice must be based on a good working knowledge
of current systems: in a recent meeting where a recommen-
dation for regular testing for albuminuria in adults in the
European Union was adopted, there seemed to be little
understanding of primary care structures in which testing
could be introduced.106
Programs need to match goals with available resources, be
long term, be protected against the vagaries of political cycles,
and be accountable. There should be long-term consistency
of overall direction, but inherent flexibility, so they can
respond to experience, and changing circumstances.
Design of these approaches requires collaboration among
health-care disciplines21,61–63,107 and, ideally, across other
government sectors (e.g. nutrition, employment, education).
With renal markers predicting hugely increased rates of non-
renal morbidities and deaths, renal interests could be central
in the design process. The multidisciplinary Bellagio 11
conference in December 2005 represented such a collabora-
tive approach.108
As governments in developing countries already know,
primary prevention will largely be driven by improved
socioeconomic status, a multi-generational proposition.
Progress, however, can be surprisingly rapid, as shown by
the quick evolution in the Western world from the wretched
circumstances, small stature, poor health, malnutrition,
substance abuse, and 40-year life expectancy that character-
ized the urban poor at the start of the 20th century.90,91 For
minority populations in affluent countries, some targeted
interventions, like subsidies for quality fresh food in remote
areas, school lunch programs, and municipal swimming
pools, are eminently feasible.109 For mainstream populations
in the Western world, regulation of purveyors of harmful
food should be considered if public education initiatives fail.
Governments in affluent countries who pay for health care
and RRT have strong incentives to support such a process.
These are big challenges. However, concerted action can
produce monumental changes, such as the dramatic fall in
smoking in some Western countries,110 facilitated access to
drugs for HIV infection in Africa,111 and the forgiving of
much Third-World debt by the International Monetary
Fund.112 Meanwhile, one current and explicit opportunity
is represented by the Bill Gates/Bono initiative for developing
countries to develop primary care services, in which these
concepts could be embedded.113,114
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